MTOR and breast carcinoma: For example, Bhlhe40 facilitates PI3K/Akt/mTOR activation and triggers tumor progression in breast cancer, whereas it represses STAT1 expression and activates tumor suppression in clear cell carcinoma (Kiss et al., 2020).